Table 3. Synoptic representation of the differences and similarities between type 2B VWD patients with or without large VWF multimers.

2B VWD patients	Platelet count		*SPA	°MADR	VWF:Ag	§VWF:RCo ratio	^VWF:CB ratio	Platelet VWF:Ag	Large multimers	VWF activation state	VWF mutation in A1 domain	Bleeding tendency	Therapy
	Pre	Post
	DDAVP												DDAVP	Platelet	VWF/FVIII concentrates
Without multimers	↓/N	↓↓	Present	↓	↓	↓↓↓	↓↓↓	N	Absent	↑	Present	↑↑	No/Yes	No	Yes
With multimers	N	N	Present	↓	N/↓	N	N	N/↓	Present	↑	Present	↑	Yes	Yes	Yes

*Spontaneous platelet aggregation

°Minimal aggregating dose of ristocetin

§VWF:RCo/VWF:Ag

^VWF:CB/VWF:Ag.

N = normal; ↓ = reduced; ↑ = increased.